Updated:
Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals develops investigational ribosomal-readthrough medicines, including exaluren and the Almirall-partnered ZKN-013 program.
Overview
Eloxx Pharmaceuticals develops investigational small-molecule medicines designed to promote ribosomal readthrough of premature stop codons caused by nonsense mutations. Its lead candidate, exaluren, is being studied for rare kidney diseases. ZKN-013 targets rare skin diseases through a collaboration with Almirall. The programs seek to restore production of full-length proteins, but their intended mechanisms are distinct from established patient benefit or regulatory approval. Its reported principal executive office is in Arlington, MA (United States). For fiscal 2025, ended 2025-12-31, its originally reported results included revenue of USD 0; a net loss of USD 5,995,000; cash used in operations of USD 6,327,000. At that year-end, it reported total assets of USD 5,270,000 and cash and cash equivalents of USD 4,785,000.
Company overview
- Legal name
- Eloxx Pharmaceuticals, Inc.
- Former names in filing history
- Sevion Therapeutics, Inc. (2014-10-03 to 2017-12-22); SENESCO TECHNOLOGIES INC (1999-11-19 to 2014-09-29); NAVA LEISURE USA INC (1997-10-07 to 1999-05-24)
- Classification
- Public company
- Industry (SIC)
- 2836 — Biological Products, (No Diagnostic Substances)
- Headquarters
- Arlington, MA, United States
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 0001035354
Financials
Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.
| Fiscal year | Period end | Revenue | Net income | Total assets | Cash and equivalents | Operating cash flow |
|---|---|---|---|---|---|---|
| FY2025USD | $0 | -$6.0M | $5.3M | $4.8M | -$6.3M | |
| FY2022USD | — | -$36.1M | $21.1M | $19.2M | -$31.8M | |
| FY2021USD | — | -$66.7M | $45.1M | $42.3M | -$35.0M | |
| FY2020USD | — | -$34.6M | $26.5M | $24.7M | -$28.2M |
Recent SEC filings
| Form | Filed | Period | Filing |
|---|---|---|---|
| S-1 | — | S-1 | |
| 8-K | 8-K | ||
| 10-Q | 10-Q | ||
| 424B4 | — | 424B4 | |
| 8-K | 8-K | ||
| S-1 | — | S-1 | |
| 10-Q | 10-Q | ||
| 8-K | 8-K | ||
| 10-K | 10-K | ||
| 8-K | FORM 8-K | ||
| 8-K | FORM 8-K | ||
| 8-K | FORM 8-K |
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Research Eloxx Pharmaceuticals, Inc. in Altss
Track this company’s investors, transactions and relationships in Altss.